Compound could help diabetic patients walk tightrope between heperglycemia, hypoglycemia.
Where this comes from
- Record sourced from PubMed, PMID 8603330.
- Also identified by PMC identifier PMC1487539.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A pharmaceutical company is proceeding with clinical testing of a new compound that could make it easier for diabetic patients to maintain good control of blood-sugar levels. The compound, a peptide called amylin, appears to lessen wild fluctuations in blood-glucose levels by slowing the rate of gastric emptying and moderating the amount of postprandial glucose. Fran Lowry interviewed the researcher who discovered the peptide.